Pharma procurement teams spend a lot of time on price—yet too many still treat Paragraph IV diligence like an afterthought.
That’s the gap DrugPatentWatch is calling out in its latest piece: Paragraph IV filings aren’t just legal events. They’re procur…
Paragraph IV Filings: The Procurement Due Diligence Tool Most Pharma Buyers Ignore Read Post »
Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you’re a pharma executive, investor, or in-house counsel, you’ve probably heard some version of this: “A patent is a patent—protection lasts X years….
Drug patent expiry dates aren’t just legal milestones—they’re commercial clocks. And if you’re still treating them like static calendar entries, you’re leaving revenue on the table.
Here’s the uncomfortable truth: most companies don’t lose because they…
Turn Drug Patent Expiry Dates Into Your Next Sales Campaign Read Post »
Sell the line before the patent breaks.
In pharma manufacturing, timing isn’t just operational—it’s commercial. The companies that win in pre-LOE (pre–loss of exclusivity) aren’t waiting for the patent cliff to arrive. They’re building demand before …
The impact of Lyrica (pregabalin) on liver function is a topic of concern for individuals taking the medication. Lyrica is… https://www.Drugchatter.com/chat/26609/how-does-lyrica-affect-liver-function/
DrugChatter: How does lyrica affect liver function? Read Post »
The “Smarter Monopoly” Debate Is Here—And It’s About to Shape Drug Prices for Years
If you’ve ever wondered why some medicines seem to get a longer runway than others, the answer is increasingly less about science—and more about policy design. A new an…
The Smarter Monopoly: Orphan Drug Exclusivity vs. Standard Drug Patents Read Post »
Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
Biologics don’t just “expire.” They cliff.
Loss of exclusivity (LOE) for biologics can arrive like a switch—suddenly opening the door for …
Pharma’s quiet arms race isn’t just about new drugs—it’s about staying on the market.
Generic competition is supposed to be the great equalizer: once patents expire, prices fall, access expands, and payers breathe easier. But in practice, the story is …
Patients aren’t asking “about patents.” They’re asking one question: “Will I be able to get my medicine?”
If you’ve spent any time around drug pricing, generics, or biosimilars, you’ve probably noticed a disconnect. The industry debates mechanisms—excl…
Drug Switching Questions: What Patients Are Really Asking Online Read Post »
Brand teams don’t lose to generic competition because they “missed” a filing. They lose because they didn’t see the strategy coming.
In pharma, the most dangerous word isn’t “lawsuit.” It’s “evergreening”—the practice of extending exclusivity through f…
Get new actionable insights and updates from BiotechBlog
